Rationale and Design of a Randomized Study Comparing the Watchman FLX Device to DOACs in Patients with Atrial Fibrillation.
暂无分享,去创建一个
M. Mansour | C. Granger | A. Camm | K. Ellenbogen | W. Saliba | A. Natale | M. Leon | T. Christen | M. Gurol | M. Alkhouli | S. Kar | K. Huber | M. Gibson | D. Allocco | Devi G. Nair | S. Doshi | Megan Coylewright | S. Pocock | V. R. Reddy
[1] M. Price,et al. Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices. , 2022, JACC. Cardiovascular interventions.
[2] S. Willems,et al. The ALSTER-FLX Registry: 3-month outcomes following left atrial appendage occlusion employing a next-generation device, a matched-pair-analysis to EWOLUTION. , 2022, Heart rhythm.
[3] P. Neužil,et al. Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17. , 2021, Journal of the American College of Cardiology.
[4] V. Reddy,et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device , 2021, Circulation.
[5] H. Diener,et al. Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation. , 2021, JACC. Cardiovascular interventions.
[6] Jeroen J. Bax,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.
[7] P. Neužil,et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. , 2020, Journal of the American College of Cardiology.
[8] S. Windecker,et al. Left atrial appendage closure versus medical therapy for atrial fibrillation: the APPLY study. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[9] D. Delurgio,et al. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries. , 2019, Journal of the American College of Cardiology.
[10] P. Noseworthy,et al. Stroke Prevention in Nonvalvular Atrial Fibrillation: A Stakeholder Perspective. , 2018, Journal of the American College of Cardiology.
[11] D. Holmes,et al. Burden of Atrial Fibrillation-Associated Ischemic Stroke in the United States. , 2018, JACC. Clinical electrophysiology.
[12] Saibal Kar,et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.
[13] C. Torp‐Pedersen,et al. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists , 2017, European heart journal. Cardiovascular pharmacotherapy.
[14] Dhanunjaya R. Lakkireddy,et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[15] G. Lip,et al. Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. , 2016, Heart failure clinics.
[16] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[17] Saibal Kar,et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.
[18] M. Price,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.
[19] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[20] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[21] D. Atar,et al. Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .
[22] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[23] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[24] Maurice Buchbinder,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.
[25] W. Brannath,et al. A graphical approach to sequentially rejective multiple test procedures , 2009, Statistics in medicine.
[26] D. Singer,et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.
[27] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[28] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.